Table 2.
Clinical characteristics of non-small cell lung cancer patients with brain metastases harboring EGFR mutations
| Characteristics | All patients | Patients with Lung-molGPA 0–2 | Patients with Lung-molGPA 2.5–4 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TKI-naïve group (%) | TKI-resistant group (%) | p | TKI-naïve group (%) | TKI-resistant group (%) | p | TKI-naïve group (%) | TKI-resistant group (%) | p | |
| All patients | 207 (100) | 137 (100) | 142 (100) | 57 (100) | 65 (100) | 80 (100) | |||
| Gender | |||||||||
| Female | 72 (34.8) | 53 (38.7) | 45 (31.7) | 21 (36.8) | 27 (41.5) | 32 (40.0) | |||
| Male | 135 (65.2) | 84 (61.3) | 0.461 | 97 (68.3) | 36 (63.2) | 0.485 | 38 (58.5) | 48 (60.0) | 0.851 |
| Smoking | |||||||||
| Never | 97 (46.9) | 68 (49.6) | 60 (42.3) | 26 (45.6) | 37 (56.9) | 42 (52.5) | |||
| Current/former | 110 (53.1) | 69 (50.4) | 0.614 | 82 (57.7) | 31 (54.4) | 0.665 | 28 (43.1) | 38 (47.5) | 0.595 |
| Age | |||||||||
| < 70 | 162 (78.3) | 112 (81.8) | 104 (73.2) | 43 (75.4) | 58 (89.2) | 69 (86.3) | |||
| ≥ 70 | 45 (21.7) | 25 (18.2) | 0.431 | 38 (26.8) | 14 (24.6) | 0.747 | 7 (10.8) | 11 (13.7) | 0.588 |
| Histology | |||||||||
| Adenocarcinoma | 116 (56.0) | 90 (65.7) | 78 (54.9) | 34 (59.6) | 38 (58.5) | 56 (70.0) | |||
| Non-adenocarcinoma | 91 (44.0) | 47 (34.3) | 0.074 | 64 (45.1) | 23 (40.4) | 0.544 | 27 (41.5) | 24 (30.0) | 0.148 |
| KPS | |||||||||
| < 70 | 84 (40.6) | 57 (41.6) | 70 (49.3) | 36 (63.2) | 14 (21.5) | 21 (26.3) | |||
| 70–100 | 123 (59.4) | 80 (58.4) | 0.850 | 72 (50.7) | 21 (36.8) | 0.076 | 51 (78.5) | 59 (73.7) | 0.510 |
| Number of BM | |||||||||
| 1–4 | 124 (59.9) | 84 (61.3) | 80 (56.3) | 24 (42.1) | 44 (67.7) | 60 (75.0) | |||
| > 4 | 83 (40.1) | 53 (38.7) | 0.793 | 62 (43.7) | 33 (57.9) | 0.069 | 21 (32.3) | 20 (25.0) | 0.331 |
| Extracranial metastases | |||||||||
| Absent | 81 (39.1) | 47 (34.3) | 23 (16.2) | 8 (14.0) | 58 (89.2) | 39 (48.8) | |||
| Present | 126 (60.9) | 90 (65.7) | 0.365 | 119 (83.8) | 49 (86.0) | 0.704 | 7 (10.8) | 41 (51.2) | 0.352 |
| Primary disease control | |||||||||
| No | 94 (45.4) | 63 (46.0) | 72 (50.7) | 32 (56.1) | 22 (33.8) | 31 (38.8) | |||
| Yes | 113 (54.6) | 74 (54.0) | 0.917 | 70 (49.3) | 25 (43.9) | 0.488 | 43 (66.2) | 49 (61.2) | 0.542 |
Abbreviations: NSCLC Non-small-cell lung cancer, BM brain metastasis, Lung-molGPA Lung Cancer Molecular Markers Graded Prognostic Assessment, TKI tyrosine kinase inhibitors, EGFR epidermal growth factor receptor, KPS Karnofsky Performance Status